Metagenomics Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Metagenomics Sequencing Market is projected to expand from USD 3.31 Billion in 2025 to USD 7.41 Billion by 2031, achieving a CAGR of 14.38%. This growth is characterized by the direct analysis of nucleotide sequences from clinical or environmental samples, eliminating the need for microbial isolation or culture. The market is primarily underpinned by the continuous reduction in high-throughput sequencing costs and the urgent necessity for rapid, culture-independent pathogen surveillance within agricultural and healthcare industries. These foundational economic and functional drivers provide a stable basis for market development, separate from temporary technological preferences.

Nevertheless, the industry faces substantial hurdles related to the intricacy of bioinformatics pipelines and the standardization of massive genomic datasets. The absence of consistent data quality protocols creates inefficiencies in downstream analysis, thereby restricting the scalability of research for routine industrial use. According to the Pistoia Alliance in 2024, 52% of R&D professionals in the life sciences highlighted low-quality and poorly curated data as the main obstacle to adopting advanced analytics. Consequently, these data management challenges continue to impede the widespread application of metagenomics sequencing in regulated diagnostic settings.

Market Drivers

Continuous technological advancements in Next-Generation Sequencing (NGS) platforms serve as a major growth engine for the Global Metagenomics Sequencing Market, vastly improving the speed and resolution of microbial analysis. The pivot toward long-read sequencing and compact benchtop instruments enables high-precision characterization of complex samples, addressing prior issues with error rates and read lengths. These innovations are extending the reach of metagenomics from academic labs to regulated industrial and clinical settings. For instance, in its March 2025 'Annual results for the year ended 31 December 2024', Oxford Nanopore Technologies announced the launch of four new products in 2024, including the ElysION and GridION Q, designed to facilitate adoption in these regulated sectors by simplifying workflows and reducing bioinformatics complexity.

Additionally, a substantial increase in private and government funding for genomic research is fueling market expansion by supplying essential capital for therapeutic development and large-scale infrastructure. Both public and private sectors are heavily investing in microbiome-based therapies and engineering biology, acknowledging their potential to transform environmental management and healthcare. As reported by European Biotechnology Magazine in June 2025, the UK government has pledged £380 million to engineering biology, with £184 million designated for scale-up infrastructure. Private investment is equally strong; according to Pharmaceutical Technology in June 2025, the microbiome firm Enterome secured $19 million in private financing to advance its immunotherapy pipeline, ensuring that theoretical metagenomics applications translate into commercial reality.

Market Challenges

The central obstacle limiting the Global Metagenomics Sequencing Market is the profound complexity of bioinformatics pipelines coupled with a lack of unified data standards. As metagenomic processes produce immense volumes of heterogeneous sequence data, the absence of standardized protocols and formats complicates the comparison of results across different sequencing platforms or laboratories. This fragmentation causes friction in data interpretation, hindering the seamless integration of metagenomics into routine industrial and clinical workflows that demand high reproducibility. Without interoperable frameworks, valuable insights remain isolated, stalling the progression of these technologies from research environments to widespread diagnostic use.

Compounding this operational difficulty, the Pistoia Alliance reported in 2024 that 48% of life science professionals identified the lack of metadata standardization as a significant barrier to effectively leveraging experimental data. This statistic underscores that despite falling sequencing costs, the downstream challenge of managing non-standardized and unstructured information prevents organizations from scaling their operations effectively. As a result, the market faces difficulties in achieving the reliability necessary for regulatory approval in agricultural and healthcare sectors, which directly suppresses potential revenue expansion.

Market Trends

The incorporation of Machine Learning and Artificial Intelligence into data analysis is fundamentally transforming the market by addressing the bottleneck of interpreting high-dimensional data. With metagenomic datasets becoming exponentially more complex, advanced AI algorithms are increasingly utilized to expedite functional annotation and taxonomic classification, effectively overcoming the constraints of conventional bioinformatics pipelines. In January 2025, NVIDIA announced in a press release titled 'NVIDIA Partners With Industry Leaders to Advance Genomics' that its new AI-focused partnerships are targeting the $10 trillion life sciences and healthcare industry, intending to integrate accelerated computing into routine multiomics workflows to hasten genomic insights and drug discovery.

The trajectory of the market is also being diversified by the growth of Environmental DNA (eDNA) surveillance applications, which facilitate non-invasive ecosystem management and biodiversity monitoring. This approach leverages metagenomics to identify species directly from environmental samples like water and soil, providing a cost-efficient and scalable alternative to traditional physical surveying. According to a February 2025 announcement by the Minderoo Foundation regarding the 'Minderoo-IUCN Alliance', their OceanOmics team initiated a collaborative project using eDNA sequencing to assess more than 600 marine fish species, using the resulting data to pinpoint extinction risks and guide global conservation strategies.

Key Players Profiled in the Metagenomics Sequencing Market

• BGI Genomics Co Ltd.
• Eurofins Scientific SE
• Illumina Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Swift Biosciences Inc.
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Metagenomics Sequencing Market has been segmented into the following categories:

Metagenomics Sequencing Market, by Product and Service:

• Reagents & consumables
• Instruments
• Services

Metagenomics Sequencing Market, by Technology:

• Shotgun metagenomic sequencing
• 16S rRNA sequencing
• Whole genome sequencing & de novo assembly
• Meta transcriptomics

Metagenomics Sequencing Market, by Application:

• Drug discovery
• Ecological & environmental metagenomics
• Clinical diagnostics
• Biofuel
• Industrial applications

Metagenomics Sequencing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metagenomics Sequencing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.